Clinicopathological Significance of Leucine-Rich α2-Glycoprotein-1 in Sera of Patients With Pancreatic Cancer
Clinicopathological Significance of Leucine-Rich α2-Glycoprotein-1 in Sera of Patients With Pancreatic Cancer
复制标题
DOI：
10.1097/mpa.0000000000000205
复制
发表时间：
2015-01-01
期刊：
影响因子：
2.9
通讯作者：
Nagano, Hiroaki
中科院分区：
文献类型：
--
作者：
Furukawa, Kenta;Kawamoto, Koichi;Nagano, Hiroaki
目的富含亮氨酸的2-糖蛋白-1（LRG-1）是一种炎性蛋白。据报道，血清LRG-1水平可用作几种类型癌症的癌症生物标志物。在本研究中，我们调查了血清LRG-1水平作为胰腺癌的生物标志物的临床实用性。方法共124例胰腺癌患者，35例慢性胰腺炎（CP）患者和144名健康志愿者参加了这项研究。采用酶联免疫吸附法测定血清LRG-1水平。结果胰腺癌患者血清中LRG-1水平明显高于CP患者和健康志愿者。LRG-1水平随着胰腺癌临床分期的进展而增加。受试者操作曲线分析显示，碳水化合物抗原19-9和LRG-1的组合导致诊断胰腺癌的曲线下面积更高。结论血清LRG-1在胰腺癌组织中呈阳性表达，但在CP患者及癌旁正常胰腺组织中未见阳性表达。
Objectives Leucine-rich 2-glycoprotein-1 (LRG-1) is an inflammatory protein. Serum LRG-1 levels can reportedly be used as a cancer biomarker for several types of carcinoma. In the present study, we investigated the clinical usefulness of serum LRG-1 levels as a biomarker of pancreatic cancer.Methods A total of 124 patients with pancreatic cancer, 35 patients with chronic pancreatitis (CP), and 144 healthy volunteers were enrolled in the study. Serum LRG-1 levels were assayed by enzyme-linked immunosorbent assay. Immunohistochemistry was used to examine LRG-1 expression in pancreatic cancer tissues.Results Serum LRG-1 levels were significantly increased in patients with pancreatic cancer compared with CP patients and healthy volunteers. The LRG-1 levels increased with progressive clinical stages of pancreatic cancer. Receiver operator curve analysis showed that a combination of carbohydrate antigen 19-9 and LRG-1 resulted in a higher area under the curve for the diagnosis of pancreatic cancer. Positive staining was observed in all cases of pancreatic cancer, but positive signal was scarcely detected in tissues from CP patients or normal surrounding tissue.Conclusions These results suggest that serum LRG-1 is a promising biomarker for pancreatic cancer.